Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s41409-022-01618-5 | DOI Listing |
Best Pract Res Clin Gastroenterol
December 2024
Department of Gastrointestinal Surgery and Solid Organ Transplant, Amrita Institute of Medical Sciences and Research Centre, Amrita University, Kochi, Kerala, India. Electronic address:
World J Transplant
December 2024
Department of Renal Medicine, Manchester University NHS Foundation Trust, Manchester M13 9WL, United Kingdom.
Background: Focal segmental glomerulosclerosis (FSGS) often recurs after transplantation, leading to graft dysfunction and graft loss. Patients who have lost prior grafts due to recurrence are at particularly high risk of re-recurrence in subsequent grafts. Rituximab and plasma exchange have been used pre-emptively to prevent post-transplant recurrence.
View Article and Find Full Text PDFIntern Med J
January 2025
Victorian Infectious Diseases Service, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Cytomegalovirus (CMV) infections continue to be associated with significant morbidity and mortality following solid organ transplantation and haemopoietic stem cell transplantation. Advances in understanding the biology of CMV in the immunosuppressed host will translate into improved management approaches and better clinical outcomes. Updated definitions of resistant and refractory CMV infections will lead to more consistent reporting of CMV outcomes, better inform appropriate antiviral strategies and influence clinical trial design.
View Article and Find Full Text PDFDiagnostics (Basel)
November 2024
College of Nursing and Health Sciences, Jazan University, Jazan 45142, Saudi Arabia.
Human CMV, regularly reactivated by simple triggers, results in asymptomatic viral shedding, powerful cellular immune responses, and memory inflation. Immunocompetent individuals benefit from a robust immune response, which aids in viral management without causing clinically significant illness; however, immunodeficient individuals are always at a higher risk of CMV reactivation and disease. Hematopoietic stem cell transplant (HSCT) recipients are consistently at higher risk of CMV reactivation and clinically significant CMV illness due to primary disease, immunosuppression, and graft vs.
View Article and Find Full Text PDFNeth Heart J
December 2024
Department of Cardiology, Bernhoven Hospital, Uden, The Netherlands.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!